{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:45:32Z","timestamp":1780058732362,"version":"3.54.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,29]]},"DOI":"10.7759\/cureus.21708","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T14:58:07Z","timestamp":1643468287000},"source":"Crossref","is-referenced-by-count":4,"title":["Pembrolizumab-Induced Immune-Mediated Glossitis"],"prefix":"10.7759","author":[{"given":"Alwin","family":"Alias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pruthali","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan C","family":"Gowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok G","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016, 12:2777-2789. 10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"key":"ref2","unstructured":"Keytruda. Summary of Product Characteristics (2015). (2021). Accessed: 28 April 2021: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4862-z","article-title":"Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study","volume":"18","author":"Dote S","year":"2018","unstructured":"Dote S, Itakura S, Kamei K, Hira D, Noda S, Kobayashi Y, Terada T. Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study. BMC Cancer. 2018, 18:957. 10.1186\/s12885-018-4862-z","journal-title":"BMC Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrc.2016.01.002","article-title":"Geographic tongue (benign migratory glossitis) in a patient treated with Pazopanib for metastatic renal cell carcinoma","volume":"6","author":"Gilmore G","year":"2016","unstructured":"Gilmore G, Qamar S, Chaudhary UB. Geographic tongue (benign migratory glossitis) in a patient treated with Pazopanib for metastatic renal cell carcinoma. Cancer Treatment Commun. 2016, 6:1-3. 10.1016\/j.ctrc.2016.01.002","journal-title":"Cancer Treatment Commun"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061283","article-title":"Oral manifestations in melanoma patients treated with target or immunomodulatory therapies","volume":"10","author":"Dika E","year":"2021","unstructured":"Dika E, Lambertini M, Gouveia B, et al.. Oral manifestations in melanoma patients treated with target or immunomodulatory therapies. J Clin Med. 2021, 10:10.3390\/jcm10061283","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2017.10.01","article-title":"Chemotherapy induced oral mucositis: prevention is possible","volume":"7","author":"Cidon EU","year":"2018","unstructured":"Cidon EU. Chemotherapy induced oral mucositis: prevention is possible. Chin Clin Oncol. 2018, 7:6. 10.21037\/cco.2017.10.01","journal-title":"Chin Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1534735418794885","article-title":"Adjunctive treatments for the prevention of chemotherapy- and radiotherapy-induced mucositis","volume":"17","author":"Thomsen M","year":"2018","unstructured":"Thomsen M, Vitetta L. Adjunctive treatments for the prevention of chemotherapy- and radiotherapy-induced mucositis. Integr Cancer Ther. 2018, 17:1027-1047. 10.1177\/1534735418794885","journal-title":"Integr Cancer Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/84465-pembrolizumab-induced-immune-mediated-glossitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:33Z","timestamp":1707507393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/84465-pembrolizumab-induced-immune-mediated-glossitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.21708","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,29]]}}}